Sensor patch market seen growing to $65.14B by 2035

The global sensor patch market is projected to rise from $7.11 billion in 2026 to $65.14 billion by 2035, driven by Medicare reimbursement, FDA regulatory momentum and rising demand for continuous monitoring. The biggest near-term gains are expected in glucose care, with growth also tied to flexible electronics, telehealth and remote patient monitoring.

Why it matters: - Sensor patches are moving from niche wearables to reimbursable clinical tools, which could expand use in chronic disease management and remote patient monitoring. - The market’s growth could reshape how health systems, payers and device makers approach continuous monitoring, especially for diabetes and cardiac care. - The forecast implies a major shift from cash-pay consumer devices to billable healthcare products.

What happened: - The global sensor patch market reached $5.56 billion in 2025 and is forecast at $7.11 billion in 2026. - Market Research Future projects the market will reach $65.14 billion by 2035, implying a 27.9% compound annual growth rate. - The report points to U.S. Medicare reimbursement for remote physiologic monitoring and late-2024 FDA clearances for expanded continuous glucose platforms as key catalysts. - The report is available as a full PDF sample copy and as the full report.

The details: - Sensor patches are compact, lightweight devices that attach to the skin or integrate into wearables to collect physiological, environmental or activity-related data. - The devices support continuous and real-time monitoring across healthcare, fitness, sports, wellness, industrial safety and research. - Advances in miniaturized electronics, flexible materials, wireless connectivity, biosensing and low-power semiconductors are improving device capability. - The report says rising demand for remote patient monitoring, preventive healthcare, personalized wellness and data-driven decision-making is accelerating adoption. - Compared with conventional monitoring equipment, sensor patches can improve mobility and convenience while reducing the need for bulky hardware. - The report estimates chronic disease prevalence and glucose care pathways add about 6.8 percentage points to CAGR, payer reimbursement expansion adds 5.9 points, flexible and printed electronics cost decline adds 4.7 points and accelerated regulatory pathways add 3.9 points. - Diabetes affected 589 million adults worldwide in 2024, with projected growth to 853 million by 2050, and about 43% of cases remain undiagnosed. - Hypertension affects 1.28 billion adults worldwide, with only about one in five achieving control. - Medicare remote physiologic monitoring codes reimburse about $19 for device supply and $50 for the first 20 minutes of clinician review each month. - Flexible and printed electronics have cut sensing-module bill-of-materials costs by an estimated 34% since 2021. - The FDA’s Breakthrough Devices Program granted 145 designations in fiscal 2024, and wearable and continuous-sensing submissions reached decisions about 30% faster than conventional 510(k) peers. - Japan’s SAKIGAKE framework provides a similar acceleration path for domestically first-filed devices.

Between the lines: - Coverage and coding are shaping product economics as much as sensor performance. - Glucose and cardiac products have the clearest reimbursement path, while temperature and hydration claims still face case-by-case review. - Adhesive skin irritation and wear-time limits remain a major constraint, with contact dermatitis and adhesive failure driving early patch removal. - The report says reformulated adhesives can add nine to 15 months to development timelines because of biocompatibility testing. - Cybersecurity, health data exposure, reimbursement gaps outside glucose and cardiac care, specialty substrate supply concentration in East Asia and sensor drift are also listed as headwinds. - Market concentration is moderate, with an estimated Herfindahl-Hirschman Index of 900-1,100 and the top five suppliers holding roughly 45% to 55% of global revenue. - The report identifies Abbott Laboratories, DexCom, Medtronic, iRhythm Technologies, Koninklijke Philips, GE HealthCare, Baxter International, VitalConnect, LifeSignals and Sensium Healthcare as key players.

What's next: - Closed-loop drug delivery could turn sensor patches into therapeutic devices by pairing sensing with feedback-controlled dosing. - Emerging-market telehealth expansion in India, Brazil and Indonesia could support broader adoption of simplified patch designs. - Vendors are expected to push more analytics subscriptions and data monetization as hardware margins compress. - Decentralized clinical trials should increase demand for continuous, auditable physiological monitoring without site visits. - Reusable substrates and detachable electronics could reduce cost per wear-day and shape procurement decisions. - Regionally, Asia-Pacific is projected to grow fastest at 30.2% CAGR, while North America remains the largest market and Europe faces ongoing MDR recertification pressure.

The bottom line: - Sensor patches are transitioning from a wearable niche to a regulated, reimbursed monitoring platform, with diabetes care and payer policy leading the way.